Dabigatran Study in the Early Phase of Stroke. New Neuroimaging Markers and Biomarkers Study (SEDMAN STUDY)
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
SEDMAN study is a prospective multicenter investigator initiated study (IIS). The main idea
is to look by Genome Wide Association (arrays that determine more than 1 million
polymorphisms) genetic risk factors associated with response to dabigatran. To conduct the
study, the goal is to recruit 300 patients with ischemic stroke with cardioembolic etiology
treated with dabigatran and 200 treated with Acenocoumarol to determine if genetic risk
factors are associated with the occurrence of any bleeding or vascular event in a year
follow-up.